In recent years, immune checkpoint blockade (ICB) therapies targeting CTLA-4, PD-1, and PD-L1 have shown promising efficacy in various cancers, including melanoma, NSCLC, and renal cell carcinoma (50–53). The gene discussed is CD274; the disease is melanoma.